SCHEMBL14716707

SCHEMBL14716707

CC(=O)Nc1nc2[nH]c(N=NC(=O)c3ccc(C)cc3)nc2c(=O)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.46
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
FGFR1 P11362 3/20 0.40
FGFR2 P21802 3/20 0.40
FGFR3 P22607 1/20 0.40
POLB P06746 2/20 0.38
ALDH1A1 P00352 2/20 0.38
ALOX15 P16050 1/20 0.38
GDA Q9Y2T3 1/20 0.37
ADORA3 P0DMS8 3/20 0.36
MAPT P10636 1/20 0.36
BLM P54132 1/20 0.36
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
OPRK1 P41145 1/20 0.36
RAB9A P51151 1/20 0.36
KLF5 Q13887 1/20 0.36
LMNA P02545 1/20 0.34
MGAM O43451 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12320829 0.86 TDP1 (0.49) TDP1GAAKDM4EFGFR1FGFR2
SCHEMBL14716705 0.83 FGFR1 (0.53) TDP1GAAKDM4EFGFR1FGFR2
SCHEMBL14716412 0.83 KDM4E (0.39) GAAKDM4EPOLBALDH1A1MAPT
SCHEMBL14716409 0.83 KDM4E (0.39) GAAKDM4EPOLBALDH1A1MAPT
SCHEMBL14716600 0.74 ALDH1A1 (0.41) TDP1GAAKDM4EFGFR1FGFR2
SCHEMBL14716736 0.74 TDP1 (0.44) TDP1GAAKDM4EFGFR1FGFR2
SCHEMBL14729742 0.74 TDP1 (0.44) TDP1GAAKDM4EFGFR1FGFR2
SCHEMBL14729789 0.74 ALDH1A1 (0.41) TDP1GAAKDM4EFGFR1FGFR2
SCHEMBL16513138 0.71 KDM4E (0.55) TDP1GAAKDM4EFGFR1FGFR2
SCHEMBL14729780 0.70 MAPT (0.40) TDP1GAAKDM4EFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458515-B2 RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound RIKEN (JP) 2016-10-04 US disclosed
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RIKEN (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RNMT, NSUN2, RNGTT TDP1 1242/4885GAA 3753/4885KDM4E 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.